Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +62

5,959 Shares in Abbott Laboratories $ABT Acquired by First Nebraska ...

AI-generated analysis

📈 First Nebraska Trust Co purchased a new position in Abbott Laboratories valued at approximately $612,000 during the first quarter.

🏦 Multiple hedge funds including MidAtlantic Capital Management Inc. and Cornerstone Financial Management LLC added new stakes worth roughly $25,000 to $26,000 each in the fourth quarter.

💰 Abbott Laboratories reported quarterly EPS of $1.31, beating analyst consensus estimates of $1.28 by $0.03.

📊 Revenue reached $12.59 billion for the quarter, exceeding expectations of $12.52 billion and growing 13.0% year-over-year.

📉 The stock trades at a PE ratio of 34.30 with a market capitalization of $183.40 billion.

📅 Q3 2026 EPS guidance is set between $1.38 and $1.46, while full-year 2026 guidance ranges from $5.45 to $5.60.

💸 A quarterly dividend of $0.63 per share will be paid on August 17th with an ex-dividend date of July 15th.

📈 The annualized dividend yield is 2.4% based on a payout ratio of 81.55%.

🏢 Institutional investors own 75.18% of the company's outstanding shares.

🔬 Abbott operates through diagnostics, medical devices, nutritionals, and established pharmaceuticals business areas.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus a consensus of $1.28.
  • Revenue of $12.59 billion exceeded analyst estimates of $12.52 billion, demonstrating strong top-line performance.
  • The company achieved a net margin of 11.65% and a return on equity of 17.69%, indicating healthy profitability.
  • Revenue grew by 13.0% year-over-year, signaling robust business expansion.
  • Multiple hedge funds initiated new positions in the stock during the first and fourth quarters.
  • First Nebraska Trust Co invested approximately $612,000 in a new position, indicating significant institutional confidence.
  • The company maintains a solid balance sheet with a current ratio of 1.38 and a debt-to-equity ratio of 0.57.
Full Analysis
First Nebraska Trust Co acquired a new position in Abbott Laboratories (NYSE:ABT) during the first quarter, purchasing 5,959 shares valued at approximately $612,000. Several other hedge funds, including MidAtlantic Capital Management Inc., Cornerstone Financial Management LLC, and Purpose Unlimited Inc., also established or modified new stakes in the company during the fourth quarter, with individual investments ranging from roughly $25,000 to $26,000. Abbott Laboratories recently reported strong financial results for the quarter ending July 16th, posting earnings per share of $1.31 which exceeded analyst consensus estimates of $1.28. The company generated revenue of $12.59 billion, surpassing expectations of $12.52 billion, and achieved a net margin of 11.65% with revenue growing 13.0% year-over-year. Institutional ownership stands at 75.18%, reflecting significant interest from the investment community. The healthcare giant provided forward-looking guidance for Q3 2026 EPS between $1.38 and $1.46, and full-year 2026 EPS between $5.45 and $5.60, slightly below the average analyst prediction of $5.52. The company also announced a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record as of July 15th, representing an annualized yield of 2.4% and a payout ratio of 81.55%.